After primary traumatic impact, secondary injury cascades include cerebral edema, ischemia from microvascular thrombosis, excitotoxicity, and inflammatory cytokine release from activated microglia. Intracranial pressure rises, reducing cerebral perfusion and expanding injury; early mitigation (osmotic therapy, sedation, ICP monitoring) is critical.
A useful framing for traumatic brain injury (TBI) is to divide it into two distinct injuries separated in time. The primary injury occurs at the moment of impact: mechanical forces shear axons, rupture blood vessels, and contuse brain tissue. This damage is immediate and largely irreversible — no intervention can un-stretch an axon or un-rupture a vessel. What makes TBI outcomes so variable, and where clinical management actually matters, is the secondary injury: the cascade of cellular and physiological events that unfolds over the hours to days following impact and kills neurons that survived the initial blow.
From your study of stroke pathophysiology, you know that ischemia — inadequate blood flow — kills neurons rapidly because the brain has no meaningful energy reserves and depends on continuous oxygen and glucose delivery. Secondary TBI creates ischemia through two mechanisms. First, microvascular thrombosis: traumatized blood vessels trigger platelet activation and coagulation within the cerebral microcirculation, creating microscopic clots that deprive adjacent tissue of perfusion. Second, and more insidiously, cerebral edema raises intracranial pressure (ICP). The skull is a rigid compartment; when brain swelling occurs inside it, pressure rises. As ICP rises, it compresses cerebral blood vessels and reduces cerebral perfusion pressure (CPP) — the difference between mean arterial pressure and ICP. Below a CPP of roughly 50–60 mmHg, cerebral autoregulation fails and ischemia follows. This is why ICP monitoring and management are central to neurocritical care: a patient can deteriorate from a survivable primary injury if rising ICP is not controlled.
Excitotoxicity adds another layer of secondary damage. Traumatic membrane disruption triggers massive glutamate release from damaged neurons. Glutamate binds NMDA and AMPA receptors on neighboring cells, causing sustained calcium influx. You already know from inflammation and wound healing that calcium is a major intracellular signaling molecule — but at pathological concentrations it activates proteases, lipases, and kinases that degrade the cytoskeleton and mitochondrial membranes. Neurons die not from the impact, but from calcium-mediated self-digestion hours later.
Microglia, the brain's resident immune cells, become activated after TBI and release inflammatory cytokines (TNF-α, IL-1β, IL-6) — the same mediators you have studied in systemic inflammation. In the acute phase, this neuroinflammation has some defensive value, clearing debris and signaling for repair. But sustained microglial activation, particularly after repeated injuries (as in chronic traumatic encephalopathy), causes ongoing neuronal damage and white matter degeneration long after the original trauma. The clinical implications across all these pathways converge on a single principle: the window for intervention is the hours immediately following injury, and every management decision — osmotic therapy to reduce edema, sedation to reduce metabolic demand, blood pressure targets to maintain CPP, temperature control to reduce excitotoxicity — is aimed at interrupting secondary cascades that are still in motion and can still be slowed.
No topics depend on this one yet.